hotspot -WSS

hotspot

author：explore 2025-09-27 23:03:45 - browse：6531

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： How CO2 helps viruses stay alive longer in the air

leisure time

hotspot

WSS

How CO2 helps viruses stay alive longer in the air

FDA approves Moderna’s RSV vaccine, its second licensed product

Take antibiotics after sex, CDC recommends for certain risk groups

Private equity deals in Medicare Advantage declines

A disappointing year of Humira biosimilars

'Revelatory' study finds a smoking impact that remains after quitting

hotspot

hotspot

knowledge

Medical records are filled with copy

FDA approves Moderna’s RSV vaccine, its second licensed product

Walensky prepares to leave CDC — and Congress — behind

Finland to offer bird flu vaccine to select groups of people, a possible global first

BioMarin wins approval for gene therapy to treat hemophilia A

Structure Therapeutics oral GLP

As demand for Covid shots wanes, Moderna seeks its next success

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Activists slam private health insurers over coverage restrictions

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

hotspot

Take antibiotics after sex, CDC recommends for certain risk groups

UnitedHealth CEO's Medicaid comments send insurer stocks diving

STAT wants to know your pick for a great summer read or listen

Gilead might be held responsible for not developing a drug

Elevance PBM president out as customers face prescription chaos

How CO2 helps viruses stay alive longer in the air

leisure time

hotspot

explore

explore